HR
Showing 1 - 25 of >10,000
HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)
Not yet recruiting
- HR+/HER2-breast Cancer
- Standard endocrine therapy plus Apatinib
- (no location specified)
Jun 2, 2023
Gout With Hyperuricemia in Adults Trial (HR091506 tablets + of febuxostat tablets, febuxostat tablets + of HR091506 tablets)
Not yet recruiting
- Gout With Hyperuricemia in Adults
- HR091506 tablets + placebo of febuxostat tablets
- febuxostat tablets + placebo of HR091506 tablets
- (no location specified)
Nov 15, 2023
HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)
Recruiting
- HR Positive HER2 Negative Advanced Breast Cancer
-
Tianjin, China天津市肿瘤医院
May 26, 2023
Type 2 Diabetes Trial (HR20031 FDC)
Not yet recruiting
- Type 2 Diabetes
- HR20031 FDC
- (no location specified)
Jan 18, 2023
Diabetes Trial (HR011408 injection; NovoRapid®, NovoRapid®;HR011408 injection)
Not yet recruiting
- Diabetes
- HR011408 injection; NovoRapid®
- NovoRapid®；HR011408 injection
- (no location specified)
Feb 12, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- (no location specified)
Nov 21, 2022
Risarg® Combined With Endocrine Therapy or Chemotherapy in
Not yet recruiting
- HR+HER2- Advanced Breast Cancer
- Ribociclib
- Combination chemotherapy
- (no location specified)
Nov 20, 2023
Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)
Recruiting
- Breast Cancer
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023
HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)
Not yet recruiting
- HER2 Low Breast Carcinoma
- SHR-A1811 for injection
- (no location specified)
Jun 12, 2023
Ribociclib in Combination With Hormonal Therapy in HR+/HER2-
Not yet recruiting
- Breast Cancer
- ribociclib
- (no location specified)
Oct 10, 2023
Diabetes Trial (INS062 injection?INS068 injection?HR20014 injection)
Not yet recruiting
- Diabetes
- INS062 injection、INS068 injection、HR20014 injection
- (no location specified)
May 24, 2023
Breast Cancer Trial (Disitamab Vedotin+Anlotinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin+Anlotinib
- (no location specified)
Aug 14, 2023
Colorectal Cancer Trial (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV,
Not yet recruiting
- Colorectal Cancer
- HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
- HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- (no location specified)
Jul 13, 2023
Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for
Recruiting
- Breast Cancer
- Dalcelli、Exemestane、Gosserine
- Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
-
Tianjin, Tianjin, ChinaJie Ge
Aug 20, 2023
Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast
Completed
- HR+/HER2- Advanced or Metastatic Breast Cancer
-
Dublin, IrelandNovartis Pharmaceuticals
May 2, 2023
Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)
Not yet recruiting
- Hormone Receptor-positive Advanced Breast Cancer
- (no location specified)
Apr 12, 2023
Breast Cancer Trial in Tianjin (Pyrrolidine?trastuzumab?AI)
Recruiting
- Breast Cancer
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Jun 1, 2023
Parenteral Nutrition Trial (HR19006, All-in-one parenteral nutrition)
Not yet recruiting
- Parenteral Nutrition
- HR19006
- All-in-one parenteral nutrition
- (no location specified)
Mar 15, 2023
Thoracoscopic Lobectomy Trial (HR18034, Ropivacaine Hydrochloride Injection)
Not yet recruiting
- Thoracoscopic Lobectomy
- HR18034
- Ropivacaine Hydrochloride Injection
- (no location specified)
Feb 16, 2023
Breast Cancer Trial in Shantou (dose-dense nab-paclitaxel followed by EC)
Recruiting
- Breast Cancer
- dose-dense nab-paclitaxel followed by EC
-
Shantou, Guangdong, ChinaShantou Central Hospital
Feb 4, 2023
Pain, Postoperative, Depression, Postpartum Trial in Pittsburgh (Dose Level 1, Dose Level 2, Dose Level 3)
Not yet recruiting
- Pain, Postoperative
- Depression, Postpartum
- Dose Level 1
- +3 more
-
Pittsburgh, PennsylvaniaMagee Womens Hospital of UPMC
Jun 7, 2023
Young Children With Motor Disabilities Trial in Taoyuan City (Ride-On Car Training in a standing posture with a 2-hour session,
Not yet recruiting
- Young Children With Motor Disabilities
- Ride-On Car Training in a standing posture with a 2-hour session
- +2 more
-
Taoyuan City, Taoyuan County, Taiwan
- +1 more
Aug 17, 2023